Evidence of a link between the lower ADAMTS13 activity and the higher relapse rate after allo-HSCT was provided in a recent study [13], which showed that lower ADAMTS13 levels before allo-HSCT predicted higher relapse rates after transplantation in AML patients. This evidence concerns the gene ADAMTS13 and acute myeloid leukemia.